Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sophoraflavanone G** is a naturally occurring flavonoid compound isolated primarily from *Sophora flavescens* and other *Sophora* species. It is a plant-derived small molecule bearing antioxidant, anti-inflammatory, antitumor, and notable antimicrobial activities, especially against antibiotic-resistant bacteria. Mechanistically, sophoraflavanone G demonstrates anti-tumor activity via induction of apoptosis in cancer cells (e.g., triple-negative breast cancer and leukemia) mediated, at least in part, by suppression of MAPK-related pathways. In immune models, it attenuates airway hyper-responsiveness and inflammation likely by inhibiting Th2 cytokine secretion and reducing oxidative stress. Preclinical research also indicates synergism with several antibiotics, enhancing their effectivity against resistant bacterial strains. Although studied for diverse pharmacological activities, it is primarily used in research; there is no evidence of clinical approval as a pharmaceutical or dietary supplement[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sophoraflavanone G.